ABSTRACT

With PSA screening, prostate cancer is increasingly diagnosed in younger age and at earlier stage, when tumor is confined to prostate. However, 5 to 15 percent of newly diagnosed prostate cancer patients still present with clinical T3 (cT3) disease. There are some controversies about the ideal treatment of cT3 prostate cancer patients. Although the majority of men with cT3 prostate cancer are treated with radiation therapy plus androgen deprivation therapy, there no high quality randomized clinical trials that compare radiotherapy to radical prostatectomy in cT3 disease. Here, we reviewed the published literature on treatment of cT3 prostate cancer and discussed evidence based ideal treatment of cT3 prostate cancer.